Superworth

OptimizeRx price to sales ratio OPRX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
1.7×
10-year median
4.3×
Against its 10-year history
13th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.8× to 32.9×
Peer median
0.6×

OptimizeRx's price to sales ratio is 1.7× as of Oct 23, 2026.

That is below its ten-year median of 4.3×, lower than on 87% of days in the last ten years.

Over that time it ranged from 0.8× in Nov 2024 to 32.9× in Oct 2021.

The median for 10 credit services stocks of a similar size is 0.6×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.7×0.9×2.2×
20252.1×1.0×3.8×
20241.1×0.8×4.7×
20234.1×2.0×5.2×
20224.6×3.9×16.5×
202119.2×16.4×32.9×
202013.7×4.0×13.9×
20196.0×5.4×9.6×
20186.3×3.6×12.8×
20174.4×2.6×4.4×
20163.2×3.1×4.8×
20154.8×2.8×5.3×
20143.9×3.2×8.3×
20136.3×3.7×11.8×
20128.8×7.9×19.3×

Against its peers

Companies in Financial - Credit Services nearest OptimizeRx's size, closest first, today.

CompanyPrice to sales ratio
OPRXOptimizeRx1.7×
DHXDHI1.6×
CPSSConsumer Portfolio Services0.5×
SNFCASecurity National Financial0.7×
IMXIInternational Money Express0.5×
MACIMelar Acquisition Corp. I/Caymann/m
POWWOutdoor5.3×
IRHOIron Horse Acquisition IIn/m
RMRegional Management0.5×
LSAKLesaka Technologies0.5×
RMNIRimini Street0.9×
Peer median0.6×

Where OptimizeRx ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on OptimizeRx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.